January 10, 2020

Study Confirms Prognostic Value of the GRACE Discharge Score for PCI in Stable CAD Patients

January 10, 2020—Xue Yan Zhao, MD, published findings from a study to assess the predictive value of the Global Registry of Acute Coronary Events (GRACE) discharge score for patients with stable coronary artery disease (CAD) after percutaneous coronary intervention (PCI).

The investigators concluded that the GRACE discharge score is valuable for the risk stratification of death and major adverse cardiovascular and cerebrovascular events (MACCE), as well as for the prognosis to mortality for stable CAD patients who have undergone PCI. The findings are available online ahead of print in Catheterization & Cardiovascular Interventions.

The study was composed of 4,293 consecutive patients with stable CAD who underwent PCI between January 2013 and December 2013. The primary endpoint was all‐cause mortality and the secondary endpoint was MACCE.

There were 38 deaths and 394 MACCE during 2 years of follow‐up among 3,915 patients with stable CAD after PCI.

As reported in Catheterization & Cardiovascular Interventions, the investigators found the following:

  • The GRACE discharge score was significantly higher for patients who died than for those who survived (86.97 ± 23.27 vs 71.07 ± 19.84; P < .001).
  • Risk stratification of the GRACE score indicated that the mortality risk of the intermediate‐risk and high‐risk groups were 3.23‐fold (hazard ratio [HR], 3.23; range, 1.59–6.55; P = .001) and 15.31‐fold higher (HR, 15.31; range, 4.43–51.62; P < .001), respectively, than that of the low‐risk group.
  • The MACCE risk for the intermediate‐risk and high‐risk groups were 1.28‐fold (HR, 1.28; range, 1.02–1.62; P = .037) and 2.42‐fold higher (HR, 2.42; range, 1.20–4.88; P = .014), respectively.
  • The GRACE discharge score had prognostic value for mortality (area under the receiver operating characteristic curve, 0.692; P < .001).


January 13, 2020

Opsens Receives FDA Approval of OptoWire III

January 9, 2020

JenaValve Pericardial TAVR System Receives FDA Breakthrough Device Designation